Related Experiment Video
Updated: Jun 17, 2026
05:49
Author Spotlight: Studying Host-Virus Interactions with Pseudotyped Viruses
Published on: November 21, 2023
2.1K
Is PF-00835231 a Pan-SARS-CoV-2 Mpro Inhibitor? A Comparative Study
Mohammad Hassan Baig1, Tanuj Sharma1, Irfan Ahmad2
1Department of Family Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Korea.
Molecules (Basel, Switzerland)
|April 3, 2021
Summary
PF-00835231, a main protease (Mpro) inhibitor, shows high efficacy against wild-type SARS-CoV-2 and its mutants. This antiviral drug offers a promising therapeutic option for COVID-19 treatment.
Area of Science:
- Virology
- Drug Discovery
- Computational Chemistry
Background:
- The global spread of COVID-19 necessitates effective antiviral treatments.
- Mutations in SARS-CoV-2's main protease (Mpro) pose challenges for drug development.
- Mpro is a critical therapeutic target for antiviral strategies against SARS-CoV-2.
Purpose of the Study:
- To investigate the efficacy of PF-00835231, a clinical-stage Mpro inhibitor, against wild-type SARS-CoV-2 Mpro and its known mutants.
- To compare the inhibitory potential of PF-00835231 with existing Mpro inhibitors using in silico methods.
Main Methods:
- Utilized various in silico approaches for molecular docking and binding affinity analysis.
- Evaluated PF-00835231 against wild-type SARS-CoV-2 Mpro and a panel of clinically relevant Mpro mutants.
- Compared the computational efficacy of PF-00835231 with five previously identified Mpro inhibitors.
Main Results:
- PF-00835231 demonstrated significant binding affinity and inhibitory potential against the wild-type SARS-CoV-2 Mpro.
- The drug candidate exhibited high efficacy against all investigated Mpro mutants.
- Comparative analysis indicated superior or comparable performance of PF-00835231 against selected mutants.
Conclusions:
- PF-00835231 is a potent inhibitor of SARS-CoV-2 Mpro, effective against both wild-type and mutant strains.
- This Mpro inhibitor represents a promising candidate for the development of novel antiviral therapies against COVID-19.
- In silico findings support the continued clinical investigation of PF-00835231 for COVID-19 treatment.
Related Concept Videos
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...